Home LiteratureArticle Details
PMID: 21119596 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Oncogene ·Vol. 30 ·No. 13 ·2011-03-31 ·Pages 1542-50

Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ

Abstract

MicroRNAs (miRNAs) are small ∼22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3' untranslated region (3' UTRs) of target gene messenger RNAs (mRNA). Recently, mutations have been identified in both miRNAs and target genes that disrupt regulatory relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has recently been shown to be upregulated in some melanomas, and is also a target of the miRNA miR-221. Here, we describe a genetic variant in the 3' UTR of the KIT oncogene that correlates with a greater than fourfold increased risk of acral melanoma. This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression of the KIT oncogene. Consistent with the hypothesis that this is a functional variant, KIT mRNA and protein levels are both increased in the majority of samples harboring the KIT variant. This work identifies a novel genetic marker for increased heritable risk of melanoma.

MeSH Terms
3' Untranslated Regions/genetics Case-Control Studies Humans Melanoma/etiology,genetics MicroRNAs/physiology Oncogenes Protein Biosynthesis Proto-Oncogene Proteins c-kit/genetics RNA, Messenger/analysis Risk Skin Neoplasms/etiology,genetics
Chemicals
3' Untranslated Regions MIRN221 microRNA, human MicroRNAs RNA, Messenger Proto-Oncogene Proteins c-kit
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Godshalk S E
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Paranjape T
Nallur S
Speed W
Chan E
Molinaro A M
Bacchiocchi A
Hoyt K
Tworkoski K
Stern D F
Sznol M
Ariyan S
Lazova R
Halaban R
Kidd K K
Weidhaas J B
Slack F J
References (36)
36 references, click to expand
  1. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Histol Histopathol. 2009 May;24(5):643-50 PMID: 19283671
  2. Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.
    In Vitro. 1984 Nov;20(11):856-8 PMID: 6519667
  3. dbSNP: the NCBI database of genetic variation.
    Nucleic Acids Res. 2001 Jan 1;29(1):308-11 PMID: 11125122
  4. Genetic risk factors for melanoma.
    Hum Genet. 2009 Oct;126(4):499-510 PMID: 19585149
  5. Database resources of the National Center for Biotechnology Information.
    Nucleic Acids Res. 2009 Jan;37(Database issue):D5-15 PMID: 18940862
  6. MicroRNA-dependent regulation of cKit in cutaneous melanoma.
    Biochem Biophys Res Commun. 2009 Feb 13;379(3):790-4 PMID: 19126397
  7. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
    Cancer Res. 2009 Apr 15;69(8):3241-4 PMID: 19351826
  8. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells.
    Oncogene. 1993 Aug;8(8):2221-9 PMID: 7687762
  9. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.
    Cancer Res. 2008 Apr 15;68(8):2745-54 PMID: 18417445
  10. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
    Int J Cancer. 2009 Feb 15;124(4):862-8 PMID: 19035443
  11. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes.
    J Invest Dermatol. 2006 May;126(5):1102-10 PMID: 16410786
  12. Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny.
    DNA Cell Biol. 2007 Apr;26(4):209-18 PMID: 17465887
  13. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.
    Mol Biol Cell. 1992 Feb;3(2):197-209 PMID: 1372524
  14. Prevalence of KIT expression in human tumors.
    J Clin Oncol. 2004 Nov 15;22(22):4514-22 PMID: 15542802
  15. Major response to imatinib mesylate in KIT-mutated melanoma.
    J Clin Oncol. 2008 Apr 20;26(12):2046-51 PMID: 18421059
  16. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.
    Pharmacogenomics. 2009 Mar;10(3):399-416 PMID: 19290790
  17. Roles of microRNAs and their targets in cancer.
    Expert Opin Biol Ther. 2007 Dec;7(12):1833-40 PMID: 18034649
  18. Trends in dermatology: melanoma incidence.
    Arch Dermatol. 2010 Mar;146(3):318 PMID: 20231504
  19. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    N Engl J Med. 2002 Aug 15;347(7):472-80 PMID: 12181401
  20. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
    Oncogene. 1996 Dec 5;13(11):2339-47 PMID: 8957075
  21. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer.
    Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1502-5 PMID: 19164563
  22. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
    Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3 PMID: 18510589
  23. The role of microRNA genes in papillary thyroid carcinoma.
    Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 PMID: 16365291
  24. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.
    EMBO J. 1998 Aug 3;17(15):4358-69 PMID: 9687504
  25. microRNAs and cancer: an overview.
    Cell Cycle. 2008 Aug 15;7(16):2485-92 PMID: 18719380
  26. ALFRED: an allele frequency database for microevolutionary studies.
    Evol Bioinform Online. 2007 Feb 22;1:1-10 PMID: 19325849
  27. Epstein-Barr virus-mediated dysregulation of human microRNA expression.
    Cell Cycle. 2008 Nov 15;7(22):3595-600 PMID: 19001862
  28. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Clin Cancer Res. 2008 Dec 1;14(23):7726-32 PMID: 19047099
  29. Loss of c-kit expression in cultured melanoma cells.
    Oncogene. 1992 Jan;7(1):51-6 PMID: 1371338
  30. 2010 TNM staging system for cutaneous melanoma...and beyond.
    Ann Surg Oncol. 2010 Jun;17(6):1475-7 PMID: 20300965
  31. Somatic activation of KIT in distinct subtypes of melanoma.
    J Clin Oncol. 2006 Sep 10;24(26):4340-6 PMID: 16908931
  32. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.
    Cancer Res. 2009 Sep 15;69(18):7459-65 PMID: 19738052
  33. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
    Cancer Res. 2010 Aug 15;70(16):6509-15 PMID: 20647319
  34. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.
    Int J Cancer. 1992 Sep 9;52(2):197-201 PMID: 1381702
  35. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Cancer Res. 2008 Oct 15;68(20):8535-40 PMID: 18922928
  36. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
    Cancer Res. 2008 Jul 15;68(14):5743-52 PMID: 18632627
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
1476-5594
Published
2011-03-31
Epub
2010-00-29
Pages
1542-50
Language
English
Region
England
NLM ID
8711562
PMCID
PMC3069149
Subset
IM
Grants
NCI NIH HHS · K08 CA124484 · United States
NCI NIH HHS · P50 CA121974-05 · United States
NIGMS NIH HHS · 1 P01 GM057672 · United States
NCRR NIH HHS · UL1 RR024139 · United States
NCI NIH HHS · K08 CA124484-05 · United States
NCI NIH HHS · P50 CA121974 · United States
NIGMS NIH HHS · P01 GM057672-10 · United States
NCI NIH HHS · 1 P50 CA121974 · United States
NIGMS NIH HHS · P01 GM057672 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com